P19-52 LB. Assessing and restructuring foreign gene insertion sites for enhanced stability of modified Vaccinia virus ankara recombinants expressing HIV genes

por Wyatt, L, Earl, P, Moss, B
Publicado 2009

GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges

por Robinson, H, Kannanganat, S, Gangadhara, S, Lai, L, Yu, T, Kozlowski, P, Earl, P, Moss, B, Amara, RR
Publicado 2012

OA07-03. Influence of preexisting vaccinia immunity on a DNA/MVA SIV vaccine, decreased cellular immunity but enhanced control of a pathogenic SIV challenge

por Kannanganat, S, Nigam, P, Velu, V, Earl, P, Lai, L, Lawson, B, Chennareddi, L, Wilson, R, Kozlowski, P, Moss, B, Robinson, H, Amara, R
Publicado 2009

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections

por Kwa, S, Sadagopal, S, Hong, J, Gangadhara, S, Basu, R, Lai, L, Iyer, S, Araki, K, Earl, PL, Wyatt, L, Villinger, F, Moss, B, Ahmed, R, Amara, RR
Publicado 2012

The efficacy of ‘static’ training interventions for improving indices of cardiorespiratory fitness in premenopausal females

por Herrod, P. J. J., Blackwell, J. E. M., Moss, B. F., Gates, A., Atherton, P. J., Lund, J. N., Williams, J. P., Phillips, B. E.
Publicado 2018

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting

por Robinson, HL, Amara, RR, Lai, L, Xu, Y, De Rosa, S, Defawe, O, Sato, A, Tomaras, GD, Qin, L, Moss, B, Wyatt, LS, Hay, C, Goepfert, P
Publicado 2009

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial

por Currier, JR, De Souza, M, Ratto-Kim, S, Paris, R, Nguay, V, Cox, J, Earl, P, Moss, B, Sriplienchan, S, Thongcharoen, P, Kim, J, Robb, M, Michael, N, Marovich, M
Publicado 2009

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV

por Hinkula, J, Petkov, S, Ljungberg, K, Hallengärd, D, Bråve, A, Isaguliants, M, Falkeborn, T, Sharma, S, Liakina, V, Robb, M, Eller, M, Moss, B, Biberfeld, G, Sandström, E, Nilsson, C, Markland, K, Blomberg, P, Wahren, B
Publicado 2017

Analysis of the Monkeypox Virus Genome

por Shchelkunov, S.N., Totmenin, A.V., Safronov, P.F., Mikheev, M.V., Gutorov, V.V., Ryazankina, O.I., Petrov, N.A., Babkin, I.V., Uvarova, E.A., Sandakhchiev, L.S., Sisler, J.R., Esposito, J.J., Damon, I.K., Jahrling, P.B., Moss, B.
Publicado 2002

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA

por Bakari, M, Aboud, S, Nilsson, C, Francis, J, Buma, D, Moshiro, C, Aris, EA, Lyamuya, E, Janabi, M, Mbwana, J, Mwanyika, L, Stout, R, Hejdeman, B, Brave, A, Robb, M, Marovich, M, Michael, N, Earl, P, Moss, B, Wahren, B, Biberfeld, G, Pallangyo, K, Mhalu, F, Sandstrom, E
Publicado 2009